Knockdown of E2F2 inhibits tumorigenicity, but preserves stemness of human embryonic stem cells

• Published in: Stem cells and development Vol. 23; no. 11; p. 1266
• Main Authors: Suzuki, Daniela Emi, Nakahata, Adriana Miti, Okamoto, Oswaldo Keith
• Format: Journal Article
• Language: English
• Published: United States 01-06-2014
• Subjects: Animals; Carcinogenesis - genetics; Cell Differentiation - genetics; Cell Proliferation; Cells, Cultured; E2F2 Transcription Factor - genetics; Embryonic Stem Cells - metabolism; Embryonic Stem Cells - physiology; Gene Knockdown Techniques; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Teratoma - genetics; Teratoma - pathology
• ISSN: 1557-8534
• DOI: 10.1089/scd.2013.0592

Tumorigenicity of human pluripotent stem cells is a major threat limiting their application in cell therapy protocols. It remains unclear, however, whether suppression of tumorigenic potential can be achieved without critically affecting pluripotency. A previous study has identified hyperexpressed genes in cancer stem cells, among which is E2F2, a gene involved in malignant transformation and stem cell self-renewal. Here we tested whether E2F2 knockdown would affect the proliferative capacity and tumorigenicity of human embryonic stem cells (hESC). Transient E2F2 silencing in hESC significantly inhibited expression of the proto-oncogenes BMI1 and HMGA1, in addition to proliferation of hESC, indicated by a higher proportion of cells in G1, fewer cells in G2/M phase, and a reduced capacity to generate hESC colonies in vitro. Nonetheless, E2F2-silenced cells kept expression of typical pluripotency markers and displayed differentiation capacity in vitro. More importantly, E2F2 knockdown in hESC significantly inhibited tumor growth in vivo, which was considerably smaller than tumors generated from control hESC, although displaying typical teratoma traits, a major indicator of pluripotency retention in E2F2-silenced cells. These results suggest that E2F2 knockdown can inhibit hESC proliferation and tumorigenicity without significantly harming stemness, providing a rationale to future protocols aiming at minimizing risks related to therapeutic application of cells and/or products derived from human pluripotent cells.